Rare Neurodevelopmental Disorder Linked to Missing Genetic Brake: Study Unveils New Target for Treatment
A groundbreaking new study sheds light on a rare, severe neurodevelopmental disorder previously shrouded in mystery. The research, published in New England Journal of Medicine, reveals how a missing piece of DNA, a long non-coding RNA (lncRNA) called CHASERR, triggers overproduction of a critical protein, leading to profound developmental challenges in affected children.
The disorder primarily affects brain development and function, causing symptoms such as being wheelchair-bound, non-verbal, and experiencing severe intellectual delays.
Long Non-Coding RNAs: The Uncharted Territory
This discovery highlights the immense potential of the vast “uncharted territory” within our genome, known as the non-coding DNA. While most RNAs generate proteins, lncRNAs don’t directly create proteins but act as intricate regulators of gene activity, akin to a “brake” on protein production.
“Until now, we didn’t know what most long non-coding RNAs did. Our study demonstrates that this specific lncRNA, CHASERR, directly controls the production of CHD2 protein. Essentially, when CHASERR is deleted, the “brake” is off, leading to an overproduction of CHD2,” explains Gemma Carvill, corresponding author of the study and Assistant Professor of Neurology, Pharmacology and Pediatrics at Northwestern University Feinberg School of Medicine.
A ‘Goldilocks Gene’ out of Balance
The CHD2 gene, also studied by Carvill and her team in 2013, plays a crucial role in brain function. While too little CHD2 protein causes neurodevelopmental issues, so too does too much. Their findings reveal a delicate balance required for healthy brain development, with CHD2 fitting the description of a “Goldilocks gene” – where “just right” is essential for normal function.
Hope for Families Affected by Rare Disorders: Personalized Treatments
Researchers now hope that understanding the crucial role of CHASERR in regulating CHD2 protein production will pave the way for innovative treatments.
“Manipulating CHASERR levels could become a targeted therapeutic approach,” Carvill notes. ”Our discovery offers hope not only for patients with neurodevelopmental disorders like epilepsy, autism, and intellectual disability, but also for other potentially similar disorders where long non-coding RNAs may play a key role.”
This research resonates deeply with Emma Broadbent’s family, featured in the study. After Emma was diagnosed with profound developmental challenges, her parents discovered a deletion of the CHASERR gene during genetic testing. Their collaborative efforts led them to researchers studying CHD2, ultimately contributing to this landmark discovery.
“
Emma’s dad, Brian Broadbent, reflects, “Emma suffers a lot, and now her story helps advance scientific understanding. We felt driven to contribute as much as we could, knowing it could benefit future children and families facing similar challenges.
”
Exploring the Uncharted Terrain
This study underscores a crucial point: Genetic testing typically focuses on analyzing only 1% of the human genome that encodes proteins, neglecting the vast, unexplored 99% consisting of non-coding DNA. Carvill emphasizes the need to recognize the significant potential hidden in these uncharted regions and encourages researchers to delve deeper.
“We currently know very little about how non-coding DNA contributes to human health and disease. However, findings like ours suggest that it could be pivotal in understanding various genetic disorders, leading to innovative treatment strategies.”
Looking forward, scientists predict a paradigm shift in personalized medicine as research unravels the complex interplay of non-coding RNAs with protein-coding genes.
Stay tuned for ongoing advancements in genetic research—the future of medicine depends on unlocking the secrets encoded within our entire genome!